Patents by Inventor Geoffrey Davis

Geoffrey Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8470314
    Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: June 25, 2013
    Assignee: Angelica Therapeutics, Inc.
    Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
  • Patent number: 8409578
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 2, 2013
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Patent number: 8252897
    Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: August 28, 2012
    Assignee: Angelica Therapeutics, Inc.
    Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
  • Publication number: 20120148597
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: February 17, 2012
    Publication date: June 14, 2012
    Applicants: Pfizer Inc., Amgen Fremont Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Publication number: 20120087923
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: November 14, 2011
    Publication date: April 12, 2012
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Patent number: 8143379
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: March 27, 2012
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Publication number: 20120045442
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 23, 2012
    Applicants: Pfizer Inc., Abgenix, Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Patent number: 8067011
    Abstract: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: November 29, 2011
    Assignee: Chimeros, Inc.
    Inventors: Claude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
  • Patent number: 8058418
    Abstract: Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 15, 2011
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Patent number: 7824679
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 2, 2010
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Patent number: 7807797
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 5, 2010
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Publication number: 20090274688
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: October 30, 2007
    Publication date: November 5, 2009
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Publication number: 20090221500
    Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.
    Type: Application
    Filed: December 15, 2008
    Publication date: September 3, 2009
    Applicant: Angelica Therapeutics, Inc.
    Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
  • Publication number: 20090041797
    Abstract: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.
    Type: Application
    Filed: June 20, 2008
    Publication date: February 12, 2009
    Applicant: ANGELICA THERAPEUTICS, INC.
    Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
  • Publication number: 20090010966
    Abstract: The present application relates to compositions of modified diphtheria toxin and fusion proteins containing modified diphtheria toxin that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome, as well as methods of making the compositions. The present application also relates to a polypeptide toxophore from a modified diphtheria toxin, where the modification is at least one amino acid residue at the amino acid residues 6-8, 28-30 or 289-291 of an unmodified native diphtheria toxin. Also described are fusion proteins which contain a modified diphtheria toxin and a non-diphtheria toxin fragment which contains a cell binding portion. The modified diphtheria toxins described can be used for the treatment of a malignant disease or a non-malignant disease.
    Type: Application
    Filed: June 20, 2008
    Publication date: January 8, 2009
    Applicant: ANGELICA THERAPEUTICS, INC.
    Inventors: Claude Geoffrey Davis, Deepshikha Datta
  • Patent number: 7429380
    Abstract: The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: September 30, 2008
    Assignee: Amgen Fremont Inc.
    Inventors: Nobuaki Hori, Claude Geoffrey Davis, Krisztina M. Zsebo, Aya Jakobovits
  • Publication number: 20080233116
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 25, 2008
    Applicants: Abgenix, Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Publication number: 20080233122
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 25, 2008
    Applicants: Abgenix, Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Patent number: 7411057
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: August 12, 2008
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas C Hanson, Mark J Neveu, Eileen E Mueller, Jeffrey H Hanke, Steven C Gilman, C. Geoffrey Davis, Jose R Corvalan
  • Patent number: 7364736
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: April 29, 2008
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis